TC BioPharm Plots Clinical-Stage Strategy For CAR-Modified Gamma Delta T-Cells
The UK cell therapy company has established cell therapy manufacturing facilities and plans clinical studies of CAR-modified gamma delta T-cells in cancer.
You may also be interested in...
Astellas builds on a 2013 collaboration by acquiring Mitobridge. Ardelyx is partnering with Kyowa Hakko Kirin to bring tenapanor to market in Japan. Meanwhile, Depomed, Xoma and Bristol all offload programs before the end of the year.
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.